SOMERSET, N.J.- October 2, 2014 -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has acquired the remaining stake in Redwood Bioscience Inc., and the SMARTag Antibody-Drug Conjugate (ADC) technology platform. In Catalent’s first acquisition since its IPO in July, the company continues to execute its strategy to build a differentiated technology offering and strengthen its position in the fast growing biologics market.
The acquisition follows the successful achievement of in vivo and in vitro proof of concept milestones, recent compelling in vivo toxicology data, and strong customer interest in the SMARTag technology. Catalent will acquire the remaining outstanding shares of Redwood. Redwood’s team in Emeryville, CA , will become part of Catalent’s network under the leadership of Redwood President, CSO and Founder, David Rabuka, who will continue to advance the development of the SMARTag technology as part of Catalent’s growing Biologics business.
Catalent announced in April 2013 that it had acquired an exclusive license to market the SMARTag technology and has subsequently collaborated with Redwood for the ongoing development and marketing of the platform.
“This acquisition brings to Catalent a highly differentiated technology in the SMARTag platform, as well as a high caliber and innovative scientific team,” commented John Chiminski, President and CEO, Catalent Pharma Solutions. “It is aligned with our strategic focus on innovation and technology, and further demonstrates Catalent’s ability to strengthen our position in key growth markets through internal and external investments.”
Barry Littlejohns, Catalent’s President of Advanced Delivery Technologies added, “In vivo toxicology studies have demonstrated that an ADC generated using the SMARTag platform has a better toxicity profile than a conventional ADC, and with efficacy studies, point to an improved therapeutic index. This acquisition builds on our recent investment in a state-of-the-art Biomanufacturing facility and underpins our strategy of investing in innovative technologies and differentiated solutions in the biologics space.”
The novel, site-specific SMARTag technology enables the generation of homogenous bioconjugates, engineered to improve performance and ease of manufacturing. Combined with Catalent’s proprietary GPEx® cell line expression system, its new state-of-the-art biomanufacturing Center of Excellence in Madison, Wisconsin, and broad range of analytical and fill-finish services, this latest investment marks a further expansion of Catalent’s capabilities to help customers develop more and better biologics treatments.
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in its Form 10-K release for the fiscal year ended June 30, 2014 filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.